Rachna T Shroff1, Erin B Kennedy2, Melinda Bachini3, Tanios Bekaii-Saab4, Christopher Crane5, Julien Edeline6, Anthony El-Khoueiry7, Mary Feng8, Matthew H G Katz9, John Primrose10, Heloisa P Soares11, Juan Valle12, Shishir K Maithel13. 1. 1 University of Arizona Cancer Center, Tucson, AZ. 2. 2 American Society of Clinical Oncology, Alexandria, VA. 3. 3 Cholangiocarcinoma Foundation, Billings, MO. 4. 4 Mayo Clinic, Phoenix, AZ. 5. 5 Memorial Sloan Kettering Cancer Centre, New York, NY. 6. 6 Centre Eugène Marquis, Rennes, France. 7. 7 University of Southern California Kenneth Norris Cancer Center, Los Angeles, CA. 8. 8 University of California, San Francisco, CA. 9. 9 The University of Texas MD Anderson Cancer Center, Houston, TX. 10. 10 University of Southampton, Southampton, United Kingdom. 11. 11 University of New Mexico Comprehensive Cancer Center, Albuquerque, NM. 12. 12 University of Manchester Institute of Cancer Sciences, Manchester, United Kingdom. 13. 13 Winship Cancer Institute, Emory University, Atlanta, GA.
Abstract
PURPOSE: To develop an evidence-based clinical practice guideline to assist in clinical decision making for patients with resected biliary tract cancer. METHODS: ASCO convened an Expert Panel to conduct a systematic review of the literature on adjuvant therapy for resected biliary tract cancer and provide recommended care options for this patient population. RESULTS: Three phase III randomized controlled trials, one phase II trial, and 16 retrospective studies met the inclusion criteria. RECOMMENDATIONS: Based on evidence from a phase III randomized controlled trial, patients with resected biliary tract cancer should be offered adjuvant capecitabine chemotherapy for a duration of 6 months. The dosing used in this trial is described in the qualifying statements, while it should be noted that the dose of capecitabine may also be determined by institutional and regional practices. Patients with extrahepatic cholangiocarcinoma or gallbladder cancer and a microscopically positive surgical resection margin (R1 resection) may be offered chemoradiation therapy. A shared decision-making approach is recommended, considering the risk of harm and potential for benefit associated with radiation therapy for patients with extrahepatic cholangiocarcinoma or gallbladder cancer. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines .
PURPOSE: To develop an evidence-based clinical practice guideline to assist in clinical decision making for patients with resected biliary tract cancer. METHODS: ASCO convened an Expert Panel to conduct a systematic review of the literature on adjuvant therapy for resected biliary tract cancer and provide recommended care options for this patient population. RESULTS: Three phase III randomized controlled trials, one phase II trial, and 16 retrospective studies met the inclusion criteria. RECOMMENDATIONS: Based on evidence from a phase III randomized controlled trial, patients with resected biliary tract cancer should be offered adjuvant capecitabine chemotherapy for a duration of 6 months. The dosing used in this trial is described in the qualifying statements, while it should be noted that the dose of capecitabine may also be determined by institutional and regional practices. Patients with extrahepatic cholangiocarcinoma or gallbladder cancer and a microscopically positive surgical resection margin (R1 resection) may be offered chemoradiation therapy. A shared decision-making approach is recommended, considering the risk of harm and potential for benefit associated with radiation therapy for patients with extrahepatic cholangiocarcinoma or gallbladder cancer. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines .
Authors: Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores Journal: Nat Rev Gastroenterol Hepatol Date: 2020-06-30 Impact factor: 46.802
Authors: Mohammad Y Zaidi; Ghassan K Abou-Alfa; Cecilia G Ethun; Shailesh V Shrikhande; Mahesh Goel; Bruno Nervi; John Primrose; Juan W Valle; Shishir K Maithel Journal: Chin Clin Oncol Date: 2019-08-05
Authors: Edward Christopher Dee; Morgan E Freret; Nora Horick; Ann C Raldow; Lipika Goyal; Andrew X Zhu; Aparna R Parikh; David P Ryan; Jeffrey W Clark; Jill N Allen; Cristina R Ferrone; Carlos Fernandez-Del Castillo; Kenneth K Tanabe; Lorraine C Drapek; Theodore S Hong; Motaz Qadan; Jennifer Y Wo Journal: Ann Surg Oncol Date: 2020-08-01 Impact factor: 5.344